[
  {
    "ts": null,
    "headline": "HYMPAVZI® (marstacimab) Reduced Bleeds by 93% Compared to On-Demand Treatment in Adults and Adolescents with Hemophilia A or B with Inhibitors",
    "summary": "NEW YORK, December 06, 2025--Pfizer Inc. (NYSE: PFE) today presented results from the Phase 3 BASIS study (NCT03938792) evaluating HYMPAVZI® (marstacimab) for adults and adolescents living with hemophilia A or B with inhibitors. The results demonstrated the superiority of HYMPAVZI in improving key bleeding outcomes compared to on-demand (OD) treatment with bypassing agents. HYMPAVZI was administered with a straightforward, once-weekly subcutaneous injection requiring minimal preparation and no t",
    "url": "https://finnhub.io/api/news?id=bcceae85ee95f1ea07f4c48fc2d6f6015d67bcc8e7154a42b2b2d6e9b97f2044",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765059300,
      "headline": "HYMPAVZI® (marstacimab) Reduced Bleeds by 93% Compared to On-Demand Treatment in Adults and Adolescents with Hemophilia A or B with Inhibitors",
      "id": 137726495,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "NEW YORK, December 06, 2025--Pfizer Inc. (NYSE: PFE) today presented results from the Phase 3 BASIS study (NCT03938792) evaluating HYMPAVZI® (marstacimab) for adults and adolescents living with hemophilia A or B with inhibitors. The results demonstrated the superiority of HYMPAVZI in improving key bleeding outcomes compared to on-demand (OD) treatment with bypassing agents. HYMPAVZI was administered with a straightforward, once-weekly subcutaneous injection requiring minimal preparation and no t",
      "url": "https://finnhub.io/api/news?id=bcceae85ee95f1ea07f4c48fc2d6f6015d67bcc8e7154a42b2b2d6e9b97f2044"
    }
  },
  {
    "ts": null,
    "headline": "Teva Crushes Earnings as Pfizer Struggles to Replace COVID Revenue",
    "summary": "Pfizer (NYSE: PFE) and Teva Pharmaceutical Industries (NYSE: TEVA) just reported third-quarter earnings that reveal two pharmaceutical companies moving in opposite directions. Pfizer is stabilizing after its COVID revenue collapse while Teva is accelerating through an innovation-led turnaround that has delivered 11 consecutive quarters of growth. One Declining, One Accelerating Pfizer posted Q3 revenue of ... Teva Crushes Earnings as Pfizer Struggles to Replace COVID Revenue",
    "url": "https://finnhub.io/api/news?id=e5afa0b3cc6dc664edd8ddc16e076ab7a597c23ca75b268495c0676e2ad38c03",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765032757,
      "headline": "Teva Crushes Earnings as Pfizer Struggles to Replace COVID Revenue",
      "id": 137726496,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Pfizer (NYSE: PFE) and Teva Pharmaceutical Industries (NYSE: TEVA) just reported third-quarter earnings that reveal two pharmaceutical companies moving in opposite directions. Pfizer is stabilizing after its COVID revenue collapse while Teva is accelerating through an innovation-led turnaround that has delivered 11 consecutive quarters of growth. One Declining, One Accelerating Pfizer posted Q3 revenue of ... Teva Crushes Earnings as Pfizer Struggles to Replace COVID Revenue",
      "url": "https://finnhub.io/api/news?id=e5afa0b3cc6dc664edd8ddc16e076ab7a597c23ca75b268495c0676e2ad38c03"
    }
  },
  {
    "ts": null,
    "headline": "Can Pfizer’s Recent Recovery Signal a Long Term Value Opportunity in 2025?",
    "summary": "Wondering if Pfizer is quietly turning into a value opportunity, or if the market is still too skeptical, you are not alone. That is exactly what this breakdown will unpack. After a rough few years, Pfizer's share price has ticked up 1.1% over the last week and 5.8% over the past month, even though it is still down 2.2% year to date and 40.1% over three years, with a modest 8.5% gain over the last year. Recent sentiment has been shaped by Pfizer's shifting pipeline strategy and portfolio...",
    "url": "https://finnhub.io/api/news?id=96c78dd0aee403bea18f5de6040a4440c05560993f549eba403a86d0becc6295",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765012178,
      "headline": "Can Pfizer’s Recent Recovery Signal a Long Term Value Opportunity in 2025?",
      "id": 137726497,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Wondering if Pfizer is quietly turning into a value opportunity, or if the market is still too skeptical, you are not alone. That is exactly what this breakdown will unpack. After a rough few years, Pfizer's share price has ticked up 1.1% over the last week and 5.8% over the past month, even though it is still down 2.2% year to date and 40.1% over three years, with a modest 8.5% gain over the last year. Recent sentiment has been shaped by Pfizer's shifting pipeline strategy and portfolio...",
      "url": "https://finnhub.io/api/news?id=96c78dd0aee403bea18f5de6040a4440c05560993f549eba403a86d0becc6295"
    }
  }
]